Trial Profile
A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Dermatomyositis; Myositis; Polymyositis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 26 Oct 2023 Status changed from discontinued to completed.
- 14 Nov 2022 Results of post-hoc analysis reporting safety, efficacy data through 24 weeks of double blind period and open label period during 28 weeks presented at the ACR Convergence 2022
- 04 Aug 2022 Status changed from active, no longer recruiting to discontinued because of Inability to meet protocol objectives.